Streetbeat News

Revenues

WULF

In the past three months, TeraWulf (NASDAQ:WULF) received mixed analyst ratings, with a recent shift towards a somewhat bullish outlook. The average 12-month price target is $3.88, reflecting a 3.47% increase from the previous target. Analysts from Cantor Fitzgerald and Compass Point have adjusted their ratings and price targets, indicating a nuanced view of TeraWulf's market position and financial performance. TeraWulf, a digital asset technology company, focuses on sustainable bitcoin mining in the U.S., showing significant revenue growth and operational challenges.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 5:00 pm

CVS

ELV

NVO

A study reveals Novo Nordisk's diabetes drug Ozempic could be produced for under $5, contrasting its $1,000 U.S. price tag. The study, involving Yale University and others, highlights the affordability issue in diabetes care. Major insurers like CVS Health and Elevance Health announced coverage for another Novo Nordisk drug, Wegovy, for certain Medicare patients. Novo Nordisk defends its pricing, citing significant R&D investments and efforts to ensure patient access through rebates and discounts.

Portfolio Pulse from Vandana Singh

March 28, 2024 | 4:54 pm

AXP

Analysts have updated their ratings on American Express (NYSE:AXP), showing a mix of perspectives with an average 12-month price target of $209.6, indicating a 5.93% increase from the previous target. The company's financials reveal strong performance, including a revenue growth rate of 13.27% and a net margin of 12.06%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:01 pm

MOH

Recent analyst evaluations of Molina Healthcare (NYSE:MOH) show diverse opinions, with the latest average 12-month price target being $433.67, an 8.69% increase from the previous target. Analysts' ratings range from 'Underperform' to 'Overweight', reflecting varied expectations for the company's performance. Molina Healthcare's financial overview indicates a strong market position with notable revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:01 pm

HRMY

Harmony Biosciences (NASDAQ:HRMY) was analyzed by 8 financial analysts, showing a mix of bullish to bearish sentiments. Recent ratings indicate a shift towards a more cautious outlook, with the average 12-month price target set at $42.62, reflecting an 11.42% increase from the previous target. Analyst actions vary, with some maintaining their ratings while others adjust their price targets. Harmony Biosciences, a commercial-stage pharmaceutical company, has shown strong financial health with a notable revenue growth rate of 31.26%, a net margin of 15.8%, and an exceptional ROE of 5.61%.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:00 pm

BLDR

Builders FirstSource (NYSE:BLDR) received diverse analyst ratings over the past quarter, with a shift towards more neutral positions in the last 30 days. The average 12-month price target for BLDR is now $215.43, marking a 12.79% increase from the previous target of $191.00. Analysts from firms like DA Davidson, Barclays, and RBC Capital have updated their ratings and price targets, reflecting changes in market conditions and company performance. Despite a negative revenue trend and challenges in maintaining profitability, BLDR's strong ROE and ROA indicate effective capital utilization. The company's market capitalization and debt management are also highlighted as strengths.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:00 pm

ZION

Zions Bancorp (NASDAQ:ZION) has seen varied analyst ratings over the last three months, with a recent shift towards more positive evaluations. The average 12-month price target has increased to $46.00, reflecting a 6.98% rise from the previous target. Analyst actions include both upgrades and downgrades, with price targets ranging from $40.00 to $48.00. Zions Bancorp, a regional U.S. bank, faces challenges in market capitalization, revenue growth, and net margin, but excels in ROE while maintaining a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:00 pm

SHWZ

Schwazze (OTC:SHWZ) reported a revenue increase of 8% in Q4 2023 to $43.3 million, despite a challenging competitive landscape in the cannabis retail sector, particularly in Colorado and New Mexico. The company expanded its store footprint by over 50% to 63 dispensaries. However, gross profit dropped significantly to $7.0 million from $21.7 million in the same quarter last year, leading to a net loss of $33.9 million. The company attributes the fierce competition and market pressures for the financial outcomes but remains optimistic about future growth and regulatory momentum.

Portfolio Pulse from Maureen Meehan

March 28, 2024 | 3:42 pm

LH

OPK

Laboratory Corporation Of America Holdings (NYSE:LH) has acquired select operations of Opko Health, Inc's (NASDAQ:OPK) subsidiary BioReference Health. The deal, valued at $237.5 million, involves assets generating about $100 million in annual revenue. This acquisition aims to expand Labcorp's diagnostic services reach, excluding New York and New Jersey, and is expected to enhance patient and physician experiences by providing broader access to Labcorp's laboratory services and testing capabilities. OPK shares rose 12.14% to $1.20 following the announcement.

Portfolio Pulse from Akanksha Bakshi

March 28, 2024 | 3:41 pm

LOWLF

Lowell Farms Inc (OTCQB:LOWLF), a California-based cannabis company, reported a 35% decrease in annual revenue for 2023, totaling $28.3 million, and a 19% decrease in Q4 revenue to $7.5 million. The company experienced a net loss of $37.3 million for the year and $13.1 million for Q4. Despite these challenges, Lowell Farms is optimistic about its restructuring and strategic realignments aimed at improving its operational framework and financial health.

Portfolio Pulse from Patricio Liddle

March 28, 2024 | 3:26 pm